SI
IRLA

Scharf Investments’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Scharf Investments’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-97
Closed -$1.97K – 83
2026
Q1 		$1.97K Sell
97
-358
-79% -$71.9K ﹤0.01% 70
2025
Q4 		$305K Hold
455
– – 0.01% 69
2025
Q3 		$148K Hold
455
– – ﹤0.01% 68
2025
Q2 		$150K Hold
455
– – ﹤0.01% 66
2025
Q1 		$121K Hold
455
– – ﹤0.01% 69
2024
Q4 		$170K Buy
+455
New +$137K 0.01% 68
2024
Q2 		– Sell
-455
Closed -$96.5K – 63
2024
Q1 		$96.5K Hold
455
– – ﹤0.01% 59
2023
Q4 		$95.6K Buy
+455
New +$91.1K ﹤0.01% 56

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Scharf Investments's IRLA Position: Q2 2026 in Review

Scharf Investments sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 97 shares — an estimated $1.97K sold.

Scharf Investments first reported a position in IRLA in Q4 2023 and held it in 8 quarters. The position peaked at $305K in Q4 2025. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Scharf Investments reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Scharf Investments sold 97 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $1.97K.
  • Scharf Investments first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2023 and held it in 8 quarters.
  • Scharf Investments's IRulya Therapeutics Inc. Common Stock position peaked at $305K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Scharf Investments's 13F filing for Q2 2026, filed 13 Jul 2026.